312 related articles for article (PubMed ID: 27186434)
1. Regulation of therapeutic resistance in cancers by receptor tyrosine kinases.
Chen MK; Hung MC
Am J Cancer Res; 2016; 6(4):827-42. PubMed ID: 27186434
[TBL] [Abstract][Full Text] [Related]
2. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
3. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
4. Cross talk of tyrosine kinases with the DNA damage signaling pathways.
Mahajan K; Mahajan NP
Nucleic Acids Res; 2015 Dec; 43(22):10588-601. PubMed ID: 26546517
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes.
Al-Ejeh F; Kumar R; Wiegmans A; Lakhani SR; Brown MP; Khanna KK
Oncogene; 2010 Nov; 29(46):6085-98. PubMed ID: 20818418
[TBL] [Abstract][Full Text] [Related]
6. Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?
Aveic S; Tonini GP
Cancer Cell Int; 2016; 16():62. PubMed ID: 27486382
[TBL] [Abstract][Full Text] [Related]
7. The Adenovirus E4orf4 Protein Provides a Novel Mechanism for Inhibition of the DNA Damage Response.
Brestovitsky A; Nebenzahl-Sharon K; Kechker P; Sharf R; Kleinberger T
PLoS Pathog; 2016 Feb; 12(2):e1005420. PubMed ID: 26867009
[TBL] [Abstract][Full Text] [Related]
8. Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics.
Arjumand W; Asiaf A; Ahmad ST
Methods Mol Biol; 2018; 1699():3-21. PubMed ID: 29086365
[TBL] [Abstract][Full Text] [Related]
9. Relationships between DNA repair and RTK-mediated signaling pathways.
Chabot T; Cheraud Y; Fleury F
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188495. PubMed ID: 33346130
[TBL] [Abstract][Full Text] [Related]
10. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
[TBL] [Abstract][Full Text] [Related]
11. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization.
Bhattacharya P; Shetake NG; Pandey BN; Kumar A
Int J Radiat Biol; 2018 Jul; 94(7):628-644. PubMed ID: 29775397
[TBL] [Abstract][Full Text] [Related]
13. Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas.
Mihailidou C; Karamouzis MV; Schizas D; Papavassiliou AG
Biochimie; 2017 Nov; 142():135-143. PubMed ID: 28890386
[TBL] [Abstract][Full Text] [Related]
14. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
[TBL] [Abstract][Full Text] [Related]
15. Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies.
Davalli P; Marverti G; Lauriola A; D'Arca D
Oxid Med Cell Longev; 2018; 2018():2389523. PubMed ID: 29770165
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.
Porter AC; Vaillancourt RR
Oncogene; 1998 Sep; 17(11 Reviews):1343-52. PubMed ID: 9779982
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis.
Templeton AJ; Diez-Gonzalez L; Ace O; Vera-Badillo F; Seruga B; Jordán J; Amir E; Pandiella A; Ocaña A
Cancer Treat Rev; 2014 Oct; 40(9):1048-55. PubMed ID: 25217796
[TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinases in carcinogenesis.
Zhang XY; Zhang PY
Oncol Lett; 2016 Nov; 12(5):3679-3682. PubMed ID: 27900053
[TBL] [Abstract][Full Text] [Related]
19. Understanding DNA damage response and DNA repair pathways: applications to more targeted cancer therapeutics.
Kinsella TJ
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S42-51. PubMed ID: 19393835
[TBL] [Abstract][Full Text] [Related]
20. Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer.
Sudhesh Dev S; Zainal Abidin SA; Farghadani R; Othman I; Naidu R
Front Pharmacol; 2021; 12():772510. PubMed ID: 34867402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
